From: Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
 | Condition under study | Ivermectin dosage (µg/kg) | Adverse effects rate (%) | Odds ratio or risk difference (95% CI) |
---|---|---|---|---|
Kamgno et al. [70] | Onchocerciasis | 0.96 (0.64–1.44) | ||
High dose | 800 | 14.8 | ||
Standard dose | 150 | 15 | ||
Munoz et al. [33] | Healthy volunteers | 0.907 (0.369–2.228) | ||
High dose | 401–700 | 16 | ||
Standard dose | 200–400 | 17 | ||
Smit et al. [95] | Malaria | 6·9% (− 1·9 to 15·7) | ||
High dose | 600 | 11 | ||
Standard dose | 300 | 4 | ||
Wimmersberger et al. [33] | Trichuriasis | 1.346 (0.532–3.405) | ||
High dose | 600 | 27 | ||
Standard dose | 100–400 | 22 |